6533b858fe1ef96bd12b6cf6

RESEARCH PRODUCT

Additional file 4 of Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy

subject

description

Additional file 4: Supplementary Figure 1. Design and binding properties of DO24 single chain antibody fragments. Supplementary Figure 2. Analysis by flow cytometry of cell surface MET expression. Supplementary Figure 3. Quantitative flow cytometer analysis of surface MET levels in A549 wild type, genetically modified, and not transformed human cells. Supplementary Figure 4. Analysis by flow cytometry of cell surface MET expression in carcinoma cells featuring MET overexpression due to high MET gene copy number. Supplementary Figure 5. Analysis of perforin and granzyme B concentrations in the culture supernatants of T cells co-cultured with target cells expressing different surface MET levels. Supplementary Figure 6. Analysis of cytokine expression in the culture supernatants of T cells expressing the MET-CAR co-cultured or not with target cells. Supplementary Figure 7. MET expression on carcinoma cells featuring MET gene amplification and overexpression resistant to anti-MET agents. Supplementary Figure 8. MET expression analyzed on carcinoma cells featuring MET overexpression due to transcriptional upregulation of the MET gene, present as diploid or at a low copy number.